^
Association details:
| Biomarker: | CYP11B1 rs4736349 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide
Published date:
11/22/2023
Excerpt:
...only rs4736349 in CYP11B1 in homozygous form (TT), present in 54 patients (20%), was related with a significantly worse OS (HR = 1.71, 95% CI 1.09 - 2.68, p = 0.019) and TTP (HR = 1.50, 95% CI 1.08 - 2.09, p = 0.016), and was related with a significantly less frequent PSA response (OR = 0.48, 95% CI 0.24 - 0.96, p = 0.038) on abiraterone or enzalutamide in a multivariable analysis.
DOI:
10.1016/j.biopha.2023.115890